Sorrento Therapeutics Inc (SRNE)

[cheynew]

Dr. Henry Ji to Participate in the H.C. Wainwright Virtual GLOBAL LIFE SCIENCES CONFERENCE 2021 Investor Conference
March 05 2021 - 01:06AM
GlobeNewswire Inc.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference:
H.C. WAINWRIGHT Global Life Sciences 2021 (Virtual Conference)
Sorrento’s Corporate Presentation will be available on-demand for 90 days starting on Tuesday, March 9, 2021 at 7:00 AM (Eastern Standard Time) at the following link:
https://journey.ct.events/view/59a9d08e-a747-4170-a89e-fb9199cdf325

An updated corporate presentation will also be available at www.sorrentotherapeutics.com.

About Sorrento Therapeutics, Inc.

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”, “DAR-T™”), antibody-drug conjugates (“ADCs”), and clinical stage oncolytic virus (“Seprehvir™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIGUARD™, COVI-AMG™, COVISHIELD™, Gene-MAb™, COVI-MSC™ and COVIDROPS™; and diagnostic test solutions, including COVITRACK™, COVISTIX™ and COVITRACE™.

Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on February 28, 2018.

For more information visit www.sorrentotherapeutics.com